Secretory non-pancreatic phopholipase A2 in severe sepsis: Relation to endotoxin, cytokines and thromboxane B2
Tóm tắt
Circulatory secretory non-pancreatic phospholipase A2 (snp-PLA2) was measured prospectively at the onset (day 0) of severe sepsis in 52 patients as well as on day 1 and 2 in 25 patients, in order to answer two questions: 1) does the snp-PLA2 plasma concentration differ according to the type and severity of infection? 2) what is the relation between snp-PLA2 and other mediators involved in severe sepsis, such as endotoxin, cytokines (TNFα, IL-1β, IL-6) and thromboxane B2 (the stable metabolite of thromboxane A2)? On day 0, the snp-PLA2 circulatory level was 78±17 nmol/min/ml in patients with severe sepsis as compared to 3.5±2 nmol/min/ml in 40 healthy volunteers. There was no statistical difference according to the outcome, the presence of shock, or the type of infection on day 0. However, snp-PLA2 remained elevated or even increased in patients who ultimately died, while it decreased in survivors (p=0.01 by ANOVA). The cytokine profiles during the 2-day follow-up were similar to that of snp-PLA2, but the differences were not statistically significant between survivors and non-survivors. No correlation was found between snp-PLA2 and other mediators for either initial or peak values.
Tài liệu tham khảo
Bone, R. C., Fein, A. M., Balk, R. A., Knaus, W. A., Cerra, F. B., Schein, R. M. H., Dellinger, R. P., Sibbald, W. J. and theACCP/SCCM Consensus Conference Committee Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101 (1992) 1644–1655.
Bone, R. C. Physiopathology of sepsis. Ann. Intern. Med. 115 (1991) 457–469.
Cook, J. A., Geisel, J., Halushka, P. V., Reines, H. D. Prostaglandins, thromboxanes, leukotrienes, and cytochrome P-450 metabolites of arachidonic acid. New Horizons 1 (1993) 60–69.
Guidet, B., Staikowsky, F., Offenstadt, G. Prostanoids and sepsis. In:Vincent, J. L. (ed.): Yearbook on intensive care and emergency medicine. Springer, Berlin 1992, pp. 115–126.
Petrak, R. A., Balk, R. A., Bone, R. C. Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure. Crit. Care Clin. 5 (1989) 303–314.
Pruzanski, W., Vadas, P. Phospholipase A2 — a mediator between proximal and distal effectors of inflammation. Immunol. Today 12 (1991) 143–146.
Vadas, P., Browning, J., Edelson, J., Pruzanski, W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediat. 8 (1993) 1–30.
Chang, J., Gilman, S. C., Lewis, A. J. Interleukin 1 activates phospholipase A2 in rabbit chondrocytes: a possible signal for IL-1 action. J. Immunol. 136 (1986) 1283–1287.
Crowl, R. M., Stoller, T. J., Conroy, R. R., Stoner, C. R. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 266 (1991) 2647–2651.
Pfeilschifter, J., Schalkwijk, C., Briner, V. A., Van Den Bosch, H. Cytokine-stimulated secretion of group II phospholipase A2 by rat mesangial cells: its contribution to arachidonic acid release and prostaglandin synthesis by cultured rat glomerular cells. J. Clin. Invest. 92 (1993) 2516–2523.
Vadas, P., Pruzanski, W., Stefanski, E., Ellies, L. G., Aubin, J. E., Soes, A., Melcher, A. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumor necrosis factor action. Immunol. Lett. 28 (1991) 187–194.
Mohri, M., Spriggs, D. R., Kufe, D. Effects of lipopolysaccharide on phospholipase A2 activity and tumor necrosis factor expression in HL-60 cells. J. Immunol. 144 (1990) 2678–2682.
Nakano, T., Ohara, O., Teraoka, H., Arita, H. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett. 261 (1990) 171–174.
Nakano, T., Arita, H. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett. 273 (1990) 23–26.
Pruzanski, W., Wilmore, D. W., Suffredini, A., Martich, G. D., Hoffman, A. G. D., Browning, J. L., Stefanski, E., Sternby, B., Vadas, P. Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin. Inflammation 16 (1992) 561–570.
Santos, A. A., Browning, J. L., Scheltinga, M. R., Lynch, E. A., Brown, E. F., Lawton, P., Chambers, E. A., Dougas, I., Benjamin, C. D., Dinarello, C. A., Wolff, S. M., Jacobs, D. O., Wilmore, D. W. Are events after endotoxinemia related to circulating phospholipase A2? Ann. Surg. 219 (1994) 183–192.
Vadas, P., Hay, J. B. Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can. J. Physiol. Pharmacol. 61 (1983) 561–566.
Vadas, P. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J. Lab. Clin. Med. 104 (1984) 873–881.
Vadas, P., Pruzanski, W., Stefanski, E., Sternby, B., Mustard, R., Bohnen, J., Fraser, I., Farewell, V., Bombardier, C. Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. Crit. Care Med. 16 (1988) 1–7.
Vadas, P., Scott, K., Smith, G., Rajkovic, I., Stefanski, E., Schouten, B. D., Singh, A., Pruzanski, W. Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock. Life Sci. 50 (1992) 807–811.
Sörensen, J., Kald, B., Tagesson, C., Lindahl, M. Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma. Intensive Care Med. 20 (1994) 555–561.
Uhl, W., Beger, H. G., Hoffmann, G., Hanisch, E., Schild, A., Waydhas, C., Entholzner, E., Müller, K., Kellermann, W., Vogeser, M., Leskopf, W., Zügel, M., Busch, E. W., Büchler, M. W. A multicenter study of phospholipase A2 in patients in intensive care units. J. Am. Coll. Surg. 180 (1995) 323–331.
Gijon, M. A., Perez, C., Mendez, E., Sanchez Crespo, M. Phospholipase A2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin: some implications for its functional role. Biochem. J. 306 (1995) 167–175.
Waydhas, C., Nast-Kolb, D., Jochum, M., Trupka, A., Lenk, S., Fritz, H., Duswald, K. H., Schweiberer, L. Inflammatory mediators, infection, sepsis, and multiple organ failure after severe trauma. Arch. Surg. 127 (1992) 460–467.
Uhl, W., Büchler, M., Nevalainen, T. J., Deller, A., Beger, H. G. Serum phospholipase A2 in patients with multiple injuries. J. Trauma 30 (1990) 1285–1290.
Heath, M. F., Tighe, D., Moss, R., Bennett, E. D. Relevance of serum phospholipase A2 assays to the assessment of septic shock. Crit. Care Med. 18 (1990) 766–767.
Vadas, P., Pruzanski, W. Serum phospholipase A2 values and septic shock. Crit. Care Med. 19 (1991) 988–989.
Legall, J. R., Loirat, P., Alperovitch, A., Glaser, P., Granthil, C., Mathieu, D., Mercier, P., Thomas, R., Villers, D. A simplified acute physiology score for ICU patients. Crit. Care Med. 12 (1984) 975–977.
Guidet, B., Barakett, V., Vassal, T., Petit, J. C., Offenstadt, G. Endotoxemia and bacteremia in intensive care patients with sepsis syndrome. Chest 106 (1994) 1194–1201.
Radvanyi, F., Jordan, L., Russo-Marie, F., Bon, C. A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labelled phospholipids in the presence of serum albumin. Anal. Biochem. 177 (1989) 103–109.
Rintala, E., Pulkki, K., Mertsola, J., Nevalainen, T., Nikoskelainen, J. Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. Scand. J. Infect. Dis. 27 (1995) 39–43.
Nevalainen, T. J. Serum phospholipase A2 in inflammatory disease. Clin. Chem. 39 (1993) 2453–2459.
Grönroos, J. M., Kuttila, K., Nevalainen, T. J. Group II phospholipase A2 in serum in critically ill surgical patients. Crit. Care Med. 22 (1994) 956–959.
Offenstadt, G., Pinta, P., Masliah, J., Alcindor, L. C., Hericord, P., Amstutz, P. Phospholipase and prophospholipase activities in bronchoalveolar lavage fluid in severe acute pulmonary disease with or without ARDS. Intensive Care Med. 7 (1981) 285–290.
Vadas, P., Pruzanski, W., Stefanski, E., Ruse, J., Farewell, V., McLaughlin, J., Bombardier, C. Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study. J. Lab. Clin. Med. 111 (1988) 584–590.
Guidet, B., Offenstadt, G. Interleukines et TNF dans le choc septique. Rév. Prat. (Paris) 43 (1993) 13–17.
Vadas, P., Pruzanski, W., Kim, J., Fornasier, V. The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. Am. J. Pathol. 134 (1989) 807–811.
Edelson, J. D., Vadas, P., Villar, J., Mullen, J. B. M., Pruzanski, W. Acute lung injury induced by phospholipase A2. Structural and functional changes. Am. Rev. Respir. Dis. 143 (1991) 1102–1109.
Vadas, P., Grouix, B., Stefanski, E., Koo Seen Lin, M., Pruzanski, W. The effect of lipid peroxidation on human secretory phospholipase A2-mediated degradation of cell membranes. Shock (1995) 34 (Suppl. 3) (Abstr. 111).
Mihelich, E. D.: Structure-based drug design of inhibitors of human non-pancreatic secretory phospholipase A2. Shock (1995) (Suppl. 3) (Abstr. 207).
Kramer, R. M., Roberts, E. S., Manneta, J. V., Hyslot, P. A., Jakubowski, J. A. Thrombin-induced phosphorylation and activation of calcium sensitive cytosolic phospholipase A2 in human platelets. J. Biol. Chem. 268 (1993) 26796–26804.
Vadas, P., Pruzanski, W. Biology of disease: role of secretory phospholipase A2 in the pathobiology of disease. Lab. Invest. 55 (1986) 391–404.
Weiss, J., Inada, M., Elsbach, T., Crowl, R. M. Structural determinants of the action againstEscherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J. Biol. Chem. 269 (1994) 26331–26337.
Lambeau, G., Ancian, P., Baraheim, J., Lazdunski, M. Cloning and expression of a membrane receptor for secretory phospholipase A2. J. Biol. Chem. 269 (1994) 1575–1578.